Managing hepatitis C virus infection

BMJ (Online)

Volumn 339, Issue 7711, 2009, Pages 37-42

  Nash, Kathryn L ^a   Bentley, Ian ^b   Hirschfield, Gideon M ^c  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b Hill Lane Surgery ^*  (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE; ALBINTERFERON ALPHA2B; ANTIVIRUS AGENT; BOCEPRAVIR; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; NITAZOXANIDE; NM 107; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; RETINOIC ACID; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE;

ALOPECIA; ANEMIA; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FLU LIKE SYNDROME; GOUT; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIVER DISEASE; LIVER TRANSPLANTATION; MOOD DISORDER; NAUSEA; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RASH; RETINOPATHY; REVIEW; SCREENING TEST; SIDE EFFECT; SLEEP DISORDER; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT REDUCTION; ALGORITHM; BLOOD TRANSFUSION; BODY PIERCING; CLINICAL PROTOCOL; DISEASE TRANSMISSION; NEEDLESTICK INJURY; RENAL REPLACEMENT THERAPY; RISK FACTOR; TATTOOING; TRAVEL; UNSAFE SEX;

ALGORITHMS; ANTIVIRAL AGENTS; BLOOD TRANSFUSION; BODY PIERCING; CLINICAL PROTOCOLS; HEPATITIS C, CHRONIC; HUMANS; NEEDLESTICK INJURIES; RENAL DIALYSIS; RISK FACTORS; TATTOOING; TRAVEL; UNSAFE SEX;

EID: 67650087711     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b2366     Document Type: Review

References (30)

1. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009;29(suppl 1):1-8.
2. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009;29(suppl 1):89-99.
3. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699-714.
4. Lok AS, Seeff LB,Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
5. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009;15:1537-47.
6. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790-800.
7. Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006;4:645-52.
8. Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol 2009;50:17-35.
9. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009;50:36-41.
10. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40.
11. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-74.
12. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
13. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-9.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
15. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8.
16. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
17. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology 2008;48:1387-95.
18. Litwin AH, Harris KAJ, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009;37:32-40.
19. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007;46:991-8.
20. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
21. Fried MW, Shiffman ML, Reddy KR, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
22. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
23. Shutt JD, Robathan J, Vyas SK. Impact of a clinical nurse specialist on the treatment of chronic hepatitis C. Br J Nurs 2008;17:572-5.
24. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
25. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
26. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008;47:43-50.
27. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
28. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
29. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008;57:516-24.
30. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41.